Agents and Actions

, Volume 26, Issue 1–2, pp 141–147 | Cite as

Leukotrienes and macrophage activation: Augmented cytotoxic activity and enhanced interleukin 1, tumor necrosis factor and hydrogen peroxide production

  • L. Gagnon
  • L. G. Filion
  • C. Dubois
  • M. Rola-Pleszczynski
Cytokines and Macrophage Activation


Leukotrienes (LT), and in particular LTB4, are potent inflammatory mediators and immunomodulators. In its interactions with leukocytes, LTB4 can activate numerous functions of neutrophils and modulate the activities of various lymphocyte subsets. LTB4 can also augment macrophage and monocyte cytotoxic activities and enhance their production of hydrogen peroxide and the monokines interleukin 1 and tumor necrosis factor. These observations allow a more detailed understanding of the effects of LTB4 on cellular immune and inflammatory functions.


Hydrogen Hydrogen Peroxide Tumor Necrosis Tumor Necrosis Factor Inflammatory Mediator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    B. Samuelsson,Leukotrienes: a new class of mediators of immediate hypersensitivity reaction and inflammation. InAdvances in Prostaglandin, Thromboxane and Leukotriene research. (Ed. B. Samuelsson, R. Paoletti and P. W. Ramwell) p. 1, Raven Press, New York 1983.Google Scholar
  2. [2]
    M. A. Bray, A. W. Ford-Hutchinson and J. H. Smith,Leukotriene B 4 an inflammatory mediator in vivo. Prostaglandins22, 213 (1981).PubMedGoogle Scholar
  3. [3]
    M. Rola-Pleszczynski,Immunoregulation by leukotrienes and other lipoxygenase metabolites. Immunol. Today6, 302–307 (1985).Google Scholar
  4. [4]
    D. O. Adams and T. A. Hamilton,The cell biology of macrophage activation. Am. Rev. Immunol.2, 283–318 (1984).Google Scholar
  5. [5]
    J. J. Rinehart, P. Lange, B. J. Gormus and M. E. Kaplan,Human monocyte-induced tumor cell cytotoxicity. Blood52, 211–220 (1978).PubMedGoogle Scholar
  6. [6]
    D. O. Adams and P. A. Marino,Evidence for a multistep mechanism of cytolysis by BCG-activated macrophages: the interrelationship between the capacity of cytolysis, target binding and secretion of cytolytic factor. J. Immunol.126, 981–987 (1981).PubMedGoogle Scholar
  7. [7]
    S. D. Somers, J. P. Mastin and D. O. Adams,The binding of tumor cells by murine mononuclear phagocytes can be divided into two qualitatively distinct types. J. Immunol.131, 2086–2093 (1983).PubMedGoogle Scholar
  8. [8]
    D. O. Adams,Effector mechanisms of cytolytically activated macrophages: 1. Secretion of neutral proteases and effect of protease inhibitors. J. Immunol.124, 286–292 (1980).PubMedGoogle Scholar
  9. [9]
    G. A. Currie,Activated macrophages kill tumor cells by releasing arginase. Nature273, 758–759 (1978).PubMedGoogle Scholar
  10. [10]
    J. Ferluga, H. V. Schorlemmer, L. C. Baptista and A. C. Allison,Production of the complete cleavage product C3a, by activated macrophages and its tumorolytic effects. Clin. Exp. Immunol.31, 512–517 (1978).PubMedGoogle Scholar
  11. [11]
    C. F. Nathan, S. C. Silverstein, L. H. Brukner and Z. A. Cohn,Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J. Exp. Med.149, 84–89 (1979).PubMedGoogle Scholar
  12. [12]
    C. F. Nathan, B. A. Arrick, H. W. Murray, N. M. Desantis and Z. A. Cohn,Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J. Exp. Med.153, 766–782 (1980).Google Scholar
  13. [13]
    M. K. Cathcart, D. W. Morel and G. M. Chisolm,III. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J. of Leuk. Biol.38, 341–350 (1985).Google Scholar
  14. [14]
    N. Matthews,Production of an anti-tumor cytotoxin by human monocytes. Immunol.44, 135–142 (1981).Google Scholar
  15. [15]
    A. R. Chen, K. P. McKinnon and H. S. Korin,Lipopolysaccharide (LPS) stimulates fresh human monocytes to lyse actinomycin D-treated WEHI-164 target cells via increased secretion of a monokine similar to tumor necrosis factor. J. Immunol.135, 3978–3987 (1985).PubMedGoogle Scholar
  16. [16]
    R. S. Kornbluth and T. S. Edgington,Tumor necrosis factor production by human monocytes is a regulated event: induction of TNF- mediated cellular cytotoxicity by endotoxin. J. Immunol.137, 2585–2591 (1986).PubMedGoogle Scholar
  17. [17]
    R. Feinman, D. Henriksen-Destefano, M. Tsujimoto and J. Vilcek,Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J. Immunol.138, 635–640 (1987).PubMedGoogle Scholar
  18. [18]
    S. Graves and B. Bonavida,Early events in tumor necrosis factor (TNF)-mediated cytotoxicity. Fed. Proc.46, 765 (1987).Google Scholar
  19. [19]
    V. Ruggiero, K. Latham and C. Bablioni,Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J. Immunol.138, 2711–2717 (1987).PubMedGoogle Scholar
  20. [20]
    K. Onozaki, K. Matsushima, E. S. Kleinerman, T. Saito and J. J. Oppenheim,Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity. J. Immunol.135, 314–320 (1985).PubMedGoogle Scholar
  21. [21]
    R. Jett, A. Mantovani and R. B. Herberman,Augmentation of human-monocyte-mediated cytolysis by interferon. Cell. Immunol.54, 425–434 (1980).PubMedGoogle Scholar
  22. [22]
    R. M. Schultz,Synergistic activation of macrophages by lymphokine and lipopolysaccharide: evidence for lymphokine as the primer and interferon as the trigger. J. Interferon Res.2, 459–466 (1982).PubMedGoogle Scholar
  23. [23]
    E. J. Léonard, L. P. Ruco and M. S. Mcltzer,Characterization of macrophage activation factor, a lymphokine that causes macrophages to become cytotoxic for tumor cells. Cell. Immunol.41, 347–357 (1978).PubMedGoogle Scholar
  24. [24]
    E. J. Wing, A. Waheed, R. K. Shadduck, L. S. Nagle and Stephenson,Effect of colony-stimulating factor on murine macrophages. Induction of antitumor activity. J. Clin. Invest.69, 270–276 (1982).PubMedGoogle Scholar
  25. [25]
    M. J. Thomassen, B. Barna, S. Malcolm-Kohn, M. Farmer, G. Urda, H. Wiedemann and M. Ahmad,C-reactive protein (CRP) enhances tumoricidal activity of human alveolar macrophages. Fed. Proc.46, 1502 (1987).Google Scholar
  26. [26]
    R. M. Schultz, N. A. Pavlidis, W. A. Stylos and M. A. Chirigos,Regulation of macrophage tumoricidal function: A role for prostaglandins of the E series. Science202, 320–327 (1978).PubMedGoogle Scholar
  27. [27]
    S. Taffet and S. W. Russel,Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J. Immunol.126, 424–429 (1981).PubMedGoogle Scholar
  28. [28]
    W. C. Koff and M. A. Dunegan,Modulation of macrophage-mediated tumoricidal activity by neuropeptides and neurohormones. J. Immunol.135, 350–354 (1985).PubMedGoogle Scholar
  29. [29]
    M. Rola-Pleszczynski, L. Gagnon and P. Sirois,Leukotriene B 4 augments human natural cytotoxic cell activity. Biochem. Biophys. Res. Commun.113, 531–537 (1983).PubMedGoogle Scholar
  30. [30]
    M. Rola-Pleszczynski, L. Gagnon and P. Sirois,Natural cytotoxic cell activity enhanced by leukotriene B 4:Modulation by cyclooxygenase and lipoxygenase inhibitors. InIcosanoids and Cancer pp. 235–242 (Eds: H. Thaler-Dao, A. Crastes de Paulet et R. Paoletti). Raven Press, New York 1984.Google Scholar
  31. [31]
    L. Gagnon, P. Sirois and M. Rola-Pleszczynski,Leukotriene B 4 augments natural cytotoxicity by increasing effector to target binding and by inducing the production of a cytotoxic lymphokine. Fed. Proc.43, 1989 (1984).Google Scholar
  32. [32]
    L. Gagnon, M. Girard, A. K. Sullivan and M. Rola-Pleszczynski,Augmentation of human natural cytotoxic cell activity by leukotriene B 4 mediated by enhanced effectortarget cell binding and increased lytic efficiency. Cell. Immunol.110, 243–252 (1987).PubMedGoogle Scholar
  33. [33]
    C. A. Rouzer, W. A. Scott, A. Z. Cohn, P. Blackburn and J. M. Manning,Mouse peritoneal macrophages release leukotriene C in response to a phagocytic stimulus. Proc. Natl. Acad. Sci (USA)77, 4928 (1980).Google Scholar
  34. [34]
    C. A. Rouzer, W. A. Scott, A. L. Hamill and Z. A. Cohn,Synthesis of leukotriene C and other arachidonic acid metabolites by mouse pulmonary macrophages. J. Exp. Med.155, 720–733 (1982).PubMedGoogle Scholar
  35. [35]
    A. D. Fels, N. A. Pawlowski, E. B. Cramer, T. K. King, Z. A. Cohn and W. A. Scott,Human alveolar macrophages produce leukotriene B 4. Proc. Natl. Acad. Sci (USA)79, 7866–7870 (1982).Google Scholar
  36. [36]
    R. Ophir, S. Ben-Efraim and I. L. Bonta,Leukotriene D 4 and indomethacin enhance additively the macrophage cytostatic activity in vitro towards MOPC-315 tumor cells. Int. J. Tiss. Reac.9, 189–194 (1987).Google Scholar
  37. [37]
    M. Rola-Pleszczynski and I. Lemaire,Leukotrienes augment interleukin 1 production by human monocytes. J. Immunol.135, 3958–3961 (1985).PubMedGoogle Scholar
  38. [38]
    C. A. Dinarello, I. Bishai, L. J. Rosenwasser and F. Coceani,The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin 1). Int. J. Immunopharmacol.1, 43–50 (1984).Google Scholar
  39. [39]
    M. Rola-Pleszczynski, L. Bouvrette, D. Gingras and M. Girard,Identification of interferon-γ as the lymphokine that mediates leukotriene B4-induced immunoregulation. I. Immunol.139, 513–517 (1987).Google Scholar
  40. [40]
    L. Gagnon, L. Fillion and M. Rola-Pleszczynski,Leukotriene B4 augments tumor necrosis factor production by human monocytes. Fed. Proc.46 (4), 6253 (1987).Google Scholar
  41. [41]
    N. Feuerstein, M. Foegh and P. W. Ramwell,Leukotrienes C4 and D4 induce prostaglandin and thromboxane release from rat peritoneal macrophages. Br. J. Pharmacol.72, 389–391 (1981).PubMedGoogle Scholar
  42. [42]
    E. J. Schenkelaars and I. L. Bonta,Effect of leukotriene C4 on the release of secretory products by elicited populations of rat peritoneal macrophages. Eur. J. Pharmacol.86, 477–480 (1983).PubMedGoogle Scholar
  43. [43]
    E. J. Schenkelaars and I. L. Bonta,Cyclooxygenase inhibitors promote leukotriene C4-induced release of beta-glucuronidase from rat peritoneal macrophages prostaglandin E2 suppresses. Int. J. Immunopharmacol.8, 305–311 (1986).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1989

Authors and Affiliations

  • L. Gagnon
    • 2
  • L. G. Filion
    • 1
  • C. Dubois
    • 2
  • M. Rola-Pleszczynski
    • 2
  1. 1.Department of Microbiology and Immunology, Faculty of Health SciencesUniversity of OttawaOttawaCanada
  2. 2.Immunology Division, Faculty of MedicineUniversity of SherbrookeSherbrookeCanada

Personalised recommendations